Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Receives RPD Designation for Descartes-08 in Juvenile Dermatomyositis
Details : Descartes-08 is a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Juvenile Dermatomyositis.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 09, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Doses First Patient in Phase 1 Trial of Descartes-15 mRNA CAR-T Therapy
Details : Descartes-15 is the next-generation autologous anti-BCMA mRNA-engineered mRNA CAR-T cell therapy. It is being investigated for Relapsed/Refractory Multiple Myeloma.
Brand Name : Descartes-15
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 03, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : $130.0 million
Deal Type : Private Placement
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Details : The Company intends to use the net proceeds from the financing to fund its pipeline, which includes Descartes-08, a potential first-in-class mRNA CAR-T for patients with generalized myasthenia gravis.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : $130.0 million
Deal Type : Private Placement
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for SLE.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Therapeutics Receives RMAT Designation for Descartes-08 in Myasthenia Gravis
Details : Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of MG.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cartesian Announces Positive Long-Term Data from Phase 2A Study of Descartes-08 Therapy
Details : Descartes-08 is a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). It is under phase 2 clinical development for generalized myasthenia gravis.
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : Selecta Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Details : The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of my...
Brand Name : Descartes-08
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 13, 2023
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : Selecta Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : RNA Engineered Allogeneic Human Mesenchymal Stem Cells
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : National Institutes of Health
Deal Size : $2.0 million
Deal Type : Funding
Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
Details : This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory disease...
Brand Name : Descartes-30
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 04, 2021
Lead Product(s) : RNA Engineered Allogeneic Human Mesenchymal Stem Cells
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : National Institutes of Health
Deal Size : $2.0 million
Deal Type : Funding
Details : Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies.
Brand Name : Descartes-11
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 22, 2021
LOOKING FOR A SUPPLIER?